# Ecolab Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Ecolab Inc.](/companies/ecl.md) (CIK 31462)
- Form: 10-Q
- Filed: 2021-08-05
- Accepted by EDGAR: Aug 5, 2021, 08:34 ET
- Period: 2021-06-30
- Accession: 0001558370-21-010420
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/31462/000155837021010420/ecl-20210630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/31462/000155837021010420/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $3.16bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $6.05bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $1.84bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $3.56bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2021-04-01 to 2021-06-30 | $853.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2021-01-01 to 2021-06-30 | $1.72bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $447.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | $745.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-04-01 to 2021-06-30 | $51.7m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-01-01 to 2021-06-30 | $105.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $86.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | $152.2m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | $1.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | $1.75 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | $1.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | $1.76 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 288,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 288,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | $798.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $245.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2021-01-01 to 2021-06-30 | $286.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2021-01-01 to 2021-06-30 | $70.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-06-30 | $1.40bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $5.49bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $18.53bn | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $2.88bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $11.80bn | us-gaap:Liabilities |
| Current portion of debt | at 2021-06-30 | $17.3m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2021-06-30 | $6.71bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2021-06-30 | 286,087,223 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 89,760 characters.

The following management discussion and analysis (“MD&A”) provides information we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The MD&A should be read in conjunction with both the unaudited consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020. This discussion contains various Non-GAAP Financial Measures and also contains various Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Statements” located at the end of Part I of this report.

### Comparability of Results

### ChampionX Transaction

On June 3, 2020, we completed the separation of our Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

The ChampionX business met the criteria to be reported as discontinued operations because the separation of ChampionX business was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we reported the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and all prior year balances have been revised accordingly to reflect continuing operations only.

### Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

### Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of our divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, we also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These sales are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

### OVERVIEW OF THE SECOND QUARTER ENDED JUNE 30, 2021

### Sales Performance

When comparing second quarter 2021 against second quarter 2020, sales performance was as follows:

- Reported net sales increased 18% to $3,163 million, fixed currency sales increased 13% and acquisition adjusted fixed currency sales increased 12%.
- Fixed currency sales for our Global Industrial segment increased 4% to $1,555 million. Acquisition adjusted fixed currency sales increased 3%, as strong growth in Water and Paper, led by recovering market conditions and new business wins, as well as improving trends in Food & Beverage, more than offset lower Downstream sales that reflected low-margin refinery business exits.
- Fixed currency sales for our Global Institutional & Specialty segment increased 34% to $979 million and acquisition adjusted fixed currency sales increased 33%. Strong growth in the Institutional operating segment reflected recovering markets, new business wins and pricing. Specialty sales declined versus last year’s strong gain that benefited from COVID-19 related orders.
- Fixed currency sales for our Global Healthcare & Life Sciences segment decreased 6% to $304 million. Acquisition adjusted fixed currency sales decreased 8% compared to a 20% increase last year when sales benefited from strong COVID-19 related demand. Underlying Healthcare and Life Sciences growth remained strong, driven by new business wins and increased hygiene awareness.
- Fixed currency sales and acquisition adjusted fixed currency sales for Other increased 23% to $307 million led by strong growth in Pest Elimination that was driven by recovering markets and new business wins.

### Financial Performance

When comparing second quarter 2021 against second quarter 2020, our financial performance was as follows:

- Reported operating income increased 133% to $448 million. Excluding the impact of special (gains) and charges from both 2021 and 2020 reported results, adjusted operating income increased 63% and our adjusted fixed currency operating income increased 53%.
- Net income from continuing operations attributable to Ecolab increased 141% to $311 million. Excluding the impact of special (gains) and charges and discrete tax items from both 2021 and 2020 reported results, our adjusted net income from continuing operations attributable to Ecolab increased 86%.
- Reported diluted EPS from continuing operations of $1.08 increased 145%. Excluding the impact of special (gains) and charges and discrete tax items from both 2021 and 2020 reported results, adjusted diluted EPS from continuing operations increased 88% to $1.22 in the second quarter of 2021.
- Our reported tax rate was 21.5% during the second quarter of 2021, compared to 9.5% during the second quarter of 2020. Excluding the tax rate impact of special (gains) and charges and discrete tax items from both 2021 and 2020 results, our adjusted tax rate was 19.3% during the second quarter of 2021, compared to 20.5% during the second quarter of 2020.

### RESULTS OF OPERATIONS

### Net Sales

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ ​ | ​ ​ Change | ​ ​ ​ ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Product and equipment sales | ​ | **​** | **$2,514.4** | **​** | ​ | ​ | $2,167.1 | ​ | **​** **​** | **​** | ​ | **​** | **$4,807.8** | **​** | ​ | ​ | $4,591.1 | ​ | **​** **​** |
| Service and lease sales | ​ | **​** | **648.3** | **​** | ​ | ​ | 518.6 | ​ | **​** **​** | **​** | ​ | **​** | **1,239.9** | **​** | ​ | ​ | 1,115.2 | ​ | **​** **​** |
| Reported GAAP net sales | ​ | **​** | **$3,162.7** | **​** | ​ | ​ | $2,685.7 | ​ | **18%** | **​** | ​ | **​** | **$6,047.7** | **​** | ​ | ​ | $5,706.3 | ​ | **6%** |
| Effect of foreign currency translation | ​ |  | **16.7** | **​** | ​ | ​ | 128.6 | ​ | **​** **​** | **​** | ​ |  | **22.3** | **​** | ​ | ​ | 196.6 | ​ | **​** **​** |
| Non-GAAP fixed currency sales | ​ | **​** | **$3,179.4** | **​** | ​ | ​ | $2,814.3 | ​ | **13%** | **​** | ​ | **​** | **$6,070.0** | **​** | ​ | ​ | $5,902.9 | ​ | **3%** |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ |

Product and sold equipment revenue is generated from providing cleaning, sanitizing and water treatment products or selling equipment used in combination with specialized products. Service and lease equipment revenue is generated from providing services or leasing equipment to customers. All of our sales are subject to the same economic conditions.

The percentage components of the period-over-period 2021 sales change are shown below:

| ​ ​ ​ ​ ​ ​ (percent) | ​ Second Quarter Ended June 30 2021 | ​ | ​ ​ | ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Volume | ​ | ​ | **10%** | **​** | **​** | ​ | **0%** | **​** |
| Price changes | ​ | ​ | **2** ​ | **​** | **​** | ​ | **2** ​ | **​** |
| Acquisition adjusted fixed currency sales change | ​ | ​ | **12** ​ | **​** | **​** | ​ | **1** ​ | **​** |
| Acquisitions and divestitures | ​ | ​ | **1** ​ | **​** | **​** | ​ | **2** ​ | **​** |
| Fixed currency sales change | ​ | ​ | **13** ​ | **​** | **​** | ​ | **3** ​ | **​** |
| Foreign currency translation | ​ | ​ | **4** ​ | **​** | **​** | ​ | **3** ​ | **​** |
| Reported GAAP net sales change | ​ | ​ | **18%** | **​** | **​** | ​ | **6%** | **​** |

Amounts do not necessarily sum due to rounding.

### Cost of Sales (“COS”) and Gross Profit Margin

| ​ ​ ​ ​ ​ (millions/percent) | ​ Second Quarter Ended June 30 2021 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin |
| --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment cost of sales | ​ | **$1,464.9** | ​ | ​ | **​** **​** | ​ | ​ | $1,301.5 | ​ | ​ | ​ ​ | ​ | ​ | **$2,827.8** | ​ | ​ | **​** **​** | ​ | ​ | $2,666.2 | ​ | ​ | ​ ​ |
| Service and lease cost of sales | ​ | **379.1** | ​ | ​ | **​** **​** | ​ | ​ | 334.2 | ​ | ​ | ​ ​ | ​ | ​ | **728.2** | ​ | ​ | **​** **​** | ​ | ​ | 689.7 | ​ | ​ | ​ ​ |
| Reported GAAP COS and gross margin | ​ | **$1,844.0** | ​ | ​ | **41.7%** | ​ | ​ | $1,635.7 | ​ | ​ | 39.1% | ​ | ​ | **$3,556.0** | ​ | ​ | **41.2%** | ​ | ​ | $3,355.9 | ​ | ​ | 41.2% |
| Special (gains) and charges | ​ | **3.7** | ​ |  | **​** **​** | ​ | ​ | 27.0 | ​ |  | ​ ​ | ​ | ​ | **23.3** | ​ |  | **​** **​** | ​ | ​ | 36.1 | ​ |  | ​ ​ |
| Non-GAAP adjusted COS and gross margin | **​** | **$1,840.3** | ​ | ​ | **41.8%** | ​ | ​ | $1,608.7 | ​ | ​ | 40.1% | ​ | **​** | **$3,532.7** | ​ | ​ | **41.6%** | ​ | ​ | $3,319.8 | ​ | ​ | 41.8% |

Our COS and corresponding gross profit margin (“gross margin”) are shown in the table above. Gross margin is defined as net sales less cost of sales divided by net sales.

Our reported gross margin was 41.7% and 39.1% for the second quarter of 2021 and 2020, respectively. Our reported gross margin was 41.2% for the first six months of both 2021 and 2020. Special (gains) and charges included in items impacting COS are shown within the “Special (Gains) and Charges” table on page 36.

Excluding the impact of special (gains) and charges within COS, second quarter 2021 adjusted gross margin was 41.8% and our adjusted gross margin for the first six months of 2021 was 41.6%. These percentages compared against a second quarter 2020 adjusted gross margin of 40.1% and an adjusted gross margin of 41.8% for the first six months of 2020.

Our adjusted gross margin increased when comparing the second quarter of 2021 against the second quarter of 2020, primarily reflecting the impact of increased sales volume and accelerated pricing, which more than offset increased delivered product costs, including Texas freeze impacts. Our adjusted gross margin decreased when comparing the first six months of 2021 against the first six months of 2020.

### Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expenses as a percentage of sales were 27.0% and 28.4% for the second quarter and first six months of 2021, respectively, compared to 29.4% and 29.7% for the second quarter and first six months of 2020, respectively. The decreased SG&A ratio to sales in the second quarter and first six months of 2021 was driven primarily by sales volume leverage, lower bad debt expense and cost savings, which more than offset higher variable compensation and investments in the business.

### Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statements of Income include the following items:

| ​ ​ ​ (millions) Cost of sales | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2021 ​ | ​ ​ | ​ ​ | ​ ​ ​ | ​ 2020 ​ | ​ ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 ​ | ​ ​ | ​ ​ | ​ ​ ​ | ​ 2020 ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: |
| Restructuring activities | ​ | **​** | **$3.7** | ​ | ​ | ​ | $2.6 | ​ | **​** | **$21.9** | ​ | ​ |  | $5.6 |
| Acquisition and integration activities | ​ | **​** | **-** | ​ | ​ | ​ | 2.2 | ​ | ​ | **-** | ​ | ​ | ​ | 2.6 |
| COVID-19 activities, net | ​ | **​** | **-** | ​ | ​ | ​ | 6.9 | ​ | ​ | **1.1** | ​ | ​ | ​ | 6.9 |
| Other | ​ | **​** | **-** | ​ | ​ | ​ | 15.3 | ​ | **​** | **0.3** | ​ | ​ | ​ | 21.0 |
| Cost of sales subtotal | ​ | **​** | **3.7** | ​ | ​ | ​ | 27.0 | ​ | **​** | **23.3** | ​ | ​ |  | 36.1 |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ |
| Special (gains) and charges | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ |
| Restructuring activities | ​ | **​** | **2.5** | ​ | ​ | ​ | 0.3 | ​ | **​** | **6.1** | ​ | ​ |  | 4.5 |
| Acquisition and integration activities | ​ | **​** | **1.3** | ​ | ​ | ​ | (2.6) | ​ | **​** | **2.5** | ​ | ​ | ​ | 2.8 |
| Disposal and impairment activities | ​ | **​** | **-** | ​ | ​ | ​ | 44.7 | ​ | **​** | **-** | ​ | ​ | ​ | 45.9 |
| COVID-19 activities, net | ​ | **​** | **8.3** | ​ | ​ | ​ | 10.2 | ​ | **​** | **14.7** | ​ | ​ |  | 10.2 |
| Other | ​ | **​** | **5.5** | ​ | ​ | ​ | 16.8 | ​ | **​** | **7.1** | ​ | ​ |  | 21.9 |
| Special (gains) and charges subtotal | ​ | **​** | **17.6** | ​ | ​ | ​ | 69.4 | ​ | **​** | **30.4** | ​ | ​ |  | 85.3 |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ |
| Operating income subtotal | ​ | **​** | **21.3** | ​ | ​ | ​ | 96.4 | ​ | **​** | **53.7** | ​ | ​ | ​ | 121.4 |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ |
| Interest expense, net | ​ | **​** | **-** | ​ | ​ | ​ | 0.7 | ​ | **​** | **-** | ​ | ​ | ​ | 0.7 |
| Other expense (income) | ​ | **​** | **19.6** | ​ | ​ | ​ | - | ​ | **​** | **19.6** | ​ | ​ | ​ | - |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ |
| Total special (gains) and charges | ​ | **​** | **$40.9** | **​** | ​ | ​ | $97.1 | ​ | **​** | **$73.3** | **​** | **​** | ​ | $122.1 |

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

### Restructuring activities

Restructuring activities are primarily related to the Institutional Advancement Program and Accelerate 2020, both of which are described below. Restructuring activities and related costs have been included as a component of both cost of sales and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

Further details related to our restructuring charges are included in Note 2.

#### Institutional Advancement Program

We approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance our Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging our ongoing investments in digital technology. In February 2021, we expanded the Institutional Plan. We expect that these restructuring charges will be completed by 2023, with total anticipated costs of $80 million ($60 million after tax) or $0.21 per diluted share. The costs are expected to be primarily cash expenditures for severance and facility closures. We also anticipate non-cash charges related to equipment disposals. We expect total program savings of approximately $50 million by the end of 2024. Actual costs may vary from these estimates depending on actions taken.

In the second quarter and first six months of 2021, we have recorded total restructuring charges of $2.2 million ($1.6 million after tax) or $0.01 per diluted share and $8.1 million ($6.1 million after tax) or $0.02 per diluted share, respectively, primarily related to costs to support the transition to the new sales and services structure and the disposal of equipment. We have recorded $43.3 million ($32.5 million after tax), or $0.11 per diluted share of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $11.5 million as of June 30, 2021. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Institutional Plan has delivered $18 million of cumulative cost savings with estimated annual cost savings of $50 million in continuing operations by 2024.

#### Accelerate 2020

During 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. The goals of the Plan are to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilitates and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. We now expect that the restructuring activities will be completed by the end of 2022, with total anticipated costs of $255 million ($195 million after tax), or $0.67 per diluted share, when revised for continuing operations. The remaining costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges (gains) of ($0.3) million ($0.2 million after tax), or less than $0.01 per diluted share and $1.4 million ($1.6 million after tax), or $0.01 per diluted share in the second quarter and first six months of 2021, respectively. The liability related to the Plan was $47.3 million as of the end of the second quarter of 2021. We have recorded $240.6 million ($185.4 million after tax), or $0.64 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters and continues to be funded from operating activities. The remaining liability is expected to be paid over a period of several quarters and will continue to be funded from operating activities.

The Plan has delivered $254 million of cumulative cost savings with estimated annual cost savings of $315 million in continuing operations by 2022.

#### Other Restructuring Activities

During the second quarter and first six months of 2021, we incurred restructuring charges of $4.3 million ($5.6 million after tax), or $0.02 per diluted share and $18.5 million ($16.4 million after tax), or $0.06 per diluted share, respectively, related to other immaterial restructuring activity. The charges primarily related to severance and asset write-offs. During the second quarter and first six months of 2021 and 2020, net restructuring charges related to all other prior year plans were minimal.

The restructuring liability balance for all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $16.8 million and $5.9 million as of June 30, 2021 and December 31, 2020, respectively. The increase in liability was driven by current period restructuring charges. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Cash payments during the 2021 related to all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $1.1 million.

### Acquisition and integration related costs

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income include $1.3 million ($1.0 million after tax) or less than $0.01 per diluted share and $2.5 million ($2.1 million after tax) or $0.01 per diluted share in the second quarter and first six months of 2021, respectively. Charges are related to Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), and Bioquell PLC (“Bioquell”) acquisitions and consist of integration costs, advisory and legal fees.

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income include ($2.6) million ($1.7 million after tax) or $0.01 per diluted share, and $2.8 million ($2.1 million after tax) or $0.01 per diluted share, in the second quarter and first six months of 2020, respectively. Charges are related to CID Lines, Bioquell and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs, advisory and legal fees, and hedge activity. Acquisition and integration costs reported in product and equipment cost of sales of $2.6 million ($1.9 million after tax) or $0.01 per diluted share in the first six months of 2020, on the Consolidated Statements of Income relate to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility. We also incurred $0.7 million ($0.5 million after tax) or less than $0.01 per diluted share, of interest expense in the first six months of 2020.

### Disposal and impairment charges

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statements of Income include $44.7 million ($44.1 million after tax) or $0.15 per diluted share, and $45.9 million ($45.0 million after tax) or $0.15 per diluted share in the second quarter and first six months of 2020, respectively. During the second quarter of 2020, we recorded a $28.6 million ($28.6 million after tax) or $0.10 per diluted share impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, we recorded charges of $16.1 million ($15.5 million after tax) or $0.06 per diluted share related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees. Further information related to our disposal is included in Note 3.

### COVID-19 activities

During the second quarter and first six months of 2021, we recorded charges of $4.1 million and $10.0 million, respectively, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $4.9 million and $8.4 million, respectively, during the second quarter and first six months of 2021 related to COVID-19 testing and related expenses. In addition, we received subsidies and government assistance, which were recorded as a special (gain) of ($0.7) million and ($2.6) million during the second quarter and first six months of 2021, respectively. COVID-19 pandemic charges are recorded in product and equipment sales, service and lease sales, and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges related to COVID-19 pandemic were $6.4 million or $0.02 per diluted share and $11.3 million or $0.04 per diluted share during the second quarter and first six months of 2021, respectively.

During the second quarter and first six months of 2020, we recorded charges of $26.5 million to protect wages of certain employees directly impacted by the COVID-19 pandemic. In addition, we received subsidies and government assistance, which was recorded as a special (gain) of $(9.4) million. The specific COVID-19 pandemic charges of $1.1 million are recorded in product and equipment sales on the Consolidated Statements of Income, $5.8 million in service and lease sales on the Consolidated Statements of Income and $10.2 million in special (gains) and charges on the Consolidated Statements of Income. After tax-charges related to COVID-19 pandemic were $13.2 million or $0.05 per diluted share during the second quarter and first six months of 2020.

### Other

Other special charges recorded in the first six months of 2021 in product and equipment cost of sales were $0.3 million ($0.2 million after tax) or less than $0.01 per diluted share. During the second quarter and first six months of 2020, we recorded special charges of $15.3 million ($10.5 million after tax) or $0.04 per diluted share and $21.0 million ($14.3 million after tax) or $0.05 per diluted share, respectively, recorded in product and equipment cost of sales on the Consolidated Statements of Income primarily related to a Healthcare product recall in Europe.

Other special charges of $5.5 million ($4.4 million after tax) or $0.02 per diluted share and $7.1 million ($5.6 million after tax) or $0.02 per diluted share recorded in the second quarter and first six months of 2021, respectively, relate primarily to legal reserve and certain legal charges and tax consulting fees associated with the ChampionX separation.

Other special charges of $16.8 million ($12.6 million after tax) or $0.04 per diluted share and $21.9 million ($16.5 million after tax) or $0.06 per diluted share recorded in the second quarter and first six months of 2020, respectively, relate primarily to legal reserve and certain legal charges which are recorded in special (gains) and charges on the Consolidated Statements of Income.

### Other expense (income)

During the second quarter and first six months of 2021, we incurred settlement expense recorded in other expense (income) on the Consolidated Statements of Income of $19.6 million ($14.9 million after tax), or $0.05 per diluted share, related to U.S. pension plan lump-sum payments to retirees.

### Operating Income and Operating Income Margin

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2021 2020 ​ | ​ ​ Change | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30 2021 2020 ​ | ​ ​ Change |
| --- | --- | --- | --- | --- | --- | --- |
| Reported GAAP operating income | ​ | **​** **$447.8** **​** ​ ​ $192.0 ​ | **133%** | ​ | **​** **$745.1** **​** ​ ​ $568.2 ​ | **31%** |
| Special (gains) and charges | ​ | **21.3** **​** ​ 96.4 ​ | ​ ​ | ​ | **53.7** **​** ​ 121.4 ​ | ​ ​ |
| Non-GAAP adjusted operating income | ​ | **469.1** **​** ​ 288.4 ​ | **63%** | ​ | **798.8** **​** ​ 689.6 ​ | **16%** |
| Effect of foreign currency translation | ​ | **2.3** **​** ​ 19.5 ​ | ​ ​ | ​ | **2.8** **​** ​ 27.3 ​ | ​ ​ |
| Non-GAAP adjusted fixed currency operating income | ​ | **​** **$471.4** **​** ​ ​ $307.9 ​ | **53%** | ​ | **​** **$801.6** **​** ​ ​ $716.9 ​ | **12%** |
| ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ |
| ​ | ​ | Second Quarter Ended | ​ ​ | ​ | Six Months Ended | ​ ​ |
| ​ | ​ | June 30 | ​ ​ | ​ | June 30 | ​ ​ |
| (percent) | ​ | **2021** ​ 2020 | ​ ​ | ​ | **2021** ​ 2020 | ​ ​ |
| Reported GAAP operating income margin | ​ | **​** **14.2%** ​ ​ 7.1% | ​ ​ | ​ | **​** **12.3%** ​ ​ 10.0% | ​ ​ |
| Non-GAAP adjusted operating income margin | ​ | **​** **14.8%** ​ ​ 10.7% | ​ ​ | ​ | **​** **13.2%** ​ ​ 12.1% | ​ ​ |
| Non-GAAP adjusted fixed currency operating income margin | ​ | **​** **14.8%** ​ ​ 10.9% | ​ ​ | ​ | **​** **13.2%** ​ ​ 12.1% | ​ ​ |

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by net sales.

Our reported operating income increased 133% and 31% in the second quarter and first six months of 2021, respectively, versus the comparable periods of 2020. Our reported operating income for 2021 and 2020 was impacted by special (gains) and charges; excluding the impact of special (gains) and charges from 2021 and 2020 reported results, our adjusted operating income increased 63% and 16% in the second quarter and first six months of 2021, respectively.

As shown in the previous table, foreign currency had a 10 percentage points and 4 percentage points impact on adjusted operating income growth for the second quarter and first six months of 2021, respectively. Foreign currency had a 3 percentage points and 2 percentage points impact on adjusted operating income growth for the second quarter and first six months of 2020, respectively.

### Other Expense (Income)

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: |
| Reported GAAP other expense (income) | ​ | **​** | **$2.5** | **​** | ​ | ​ | ($15.1) | ​ | **(117)%** | ​ | **​** | **($14.5)** | **​** | ​ | ​ | ($30.5) | ​ | **(52)%** |
| Special (gains) and charges | ​ | **​** | **19.6** | **​** | ​ |  | - | ​ | ​ ​ | ​ | **​** | **19.6** | **​** | ​ |  | - | ​ | ​ ​ |
| Non-GAAP adjusted other expense (income) | ​ | **​** | **($17.1)** | **​** | ​ | ​ | ($15.1) | ​ | **13%** | ​ | **​** | **($34.1)** | **​** | ​ | ​ | ($30.5) | ​ | **12%** |

Other expense was $2.5 million in the second quarter of 2021 and Other income was $15.1 million in the second quarter of 2020. Other income was $14.5 million and $30.5 million in the first six months of 2021 and 2020, respectively. The decrease in Other income was driven by a $19.6 million settlement expense related to U.S. pension plan lump-sum payments to retirees.

### Interest Expense, Net

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: |
| Reported GAAP interest expense, net | ​ | **​** | **$45.6** | **​** | ​ | ​ | $58.7 | ​ | **(22)%** | ​ | **​** | **$97.3** | **​** | ​ | ​ | $107.0 | ​ | **(9)%** |
| Special (gains) and charges | ​ | **​** | **-** | **​** | ​ |  | 0.7 | ​ | ​ ​ | ​ | **​** | **-** | **​** | ​ |  | 0.7 | ​ | ​ ​ |
| Non-GAAP adjusted interest expense, net | ​ | **​** | **$45.6** | **​** | ​ | ​ | $58.0 | ​ | **(21)%** | ​ | **​** | **$97.3** | **​** | ​ | ​ | $106.3 | ​ | **(8)%** |

Reported net interest expense was $45.6 million and $58.7 million in the second quarter of 2021 and 2020, respectively. Reported net interest expense was $97.3 million and $107.0 million in the first six months of 2021 and 2020, respectively. The decrease in interest expense when comparing 2021 against 2020 was driven primarily by a reduction in the average interest rate and average debt levels.

### Provision for Income Taxes

The following table provides a summary of our tax rate:

| ​ ​ ​ (percent) | ​ ​ ​ | ​ ​ Second Quarter Ended June 30 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ | ​ ​ Six Months Ended June 30 2021 | ​ ​ | ​ ​ 2020 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Reported GAAP tax rate | **​** | **21.5%** | **​** | 9.5% | **​** | 23.0% | **​** | 12.4% |
| Tax rate impact of: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Special (gains) and charges |  | **(0.4)** **​** | **​** | 1.9 ​ | **​** | **(0.3)** **​** | **​** | 0.9 |
| Discrete tax items |  | **(1.8)** **​** | **​** | 9.1 ​ | **​** | **(3.2)** **​** | **​** | 7.2 |
| Non-GAAP adjusted tax rate |  | **19.3%** | **​** | 20.5% |  | **19.5%** | **​** | 20.5% |

Our reported tax rate was 21.5% and 9.5% for the second quarter of 2021 and 2020, respectively, and 23.0% and 12.4% for the first six months of 2021 and 2020, respectively. The change in our tax rate for the second quarter and first six months of 2021 versus the comparable period of 2020 was driven primarily by discrete tax items. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized net tax expense related to discrete tax items of $7.7 million and $23.8. million in the second quarter and first six months of 2021, respectively. This included tax expense of $9.5 million related to prior year returns in the second quarter and first six months of 2021, and a deferred tax benefit of $0.9 million and deferred tax expense $24.2 million associated with transferring certain intangible property between affiliates in the second quarter and first six months of 2021, respectively. Share-based compensation excess tax benefit was $4.2 million and $10.8 million in the second quarter and first six months of 2021. The amount of this tax benefit is subject to variation in stock price and award exercises. The remaining discrete tax expense of $3.3 million and $0.9 million during the quarter and first six months of 2021, respectively, was primarily due to other changes in estimates.

We recognized net discrete tax benefits of $22.5 million and $44.4 million in the second quarter and first six months of 2020, respectively. This includes share-based compensation excess tax benefit of $23.3 million and $45.6 million in the second quarter and first six months of 2020, respectively. Additionally, we recognized expense of $0.6 million and $4.5 million primarily related to the filing of prior year foreign tax returns and other income tax adjustments in the second quarter and first six months of 2020, respectively. The remaining discrete expense of $0.2 million and benefit of $3.3 million was due to the accrual of interest on uncertain tax positions offset by reserve released during the quarter and the first six months of 2020, respectively.

The decrease in the second quarter and first six months of 2021 adjusted tax rate compared to 2020 was primarily due to the geographic mix of income and tax planning.

### Net Income from Continuing Operations Attributable to Ecolab

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP net income from continuing operations attributable to Ecolab | **​** | **​** | **$310.8** | **​** | ​ | ​ | $128.9 | **​** | **141%** | **​** | **​** | **$504.4** | **​** | ​ | ​ | $420.9 | **​** | **20%** |
| Adjustments: | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ |
| Special (gains) and charges, after tax | ​ |  | **34.1** | **​** | ​ | ​ | 83.3 | ​ | **​** ​ | ​ | **​** | **58.3** | **​** | ​ | ​ | 101.8 | ​ | **​** ​ |
| Discrete tax net expense (benefit) | ​ |  | **7.7** | **​** | ​ | ​ | (22.5) | ​ | **​** ​ | ​ | **​** | **23.8** | **​** | ​ | ​ | (44.4) | ​ | **​** ​ |
| Non-GAAP adjusted net income from continuing operations attributable to Ecolab | ​ | **​** | **$352.6** | **​** | ​ | ​ | $189.7 | ​ | **86%** | ​ | **​** | **$586.5** | **​** | ​ | ​ | $478.3 | ​ | **23%** |

### Diluted EPS from Continuing Operations

| ​ ​ ​ (dollars) | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ | ​ 2020 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP diluted EPS from continuing operations | **​** | **​** | **$1.08** | **​** | ​ | ​ | $ 0.44 | **​** | **145%** | **​** | **​** | **$1.75** | **​** | ​ | ​ | $ 1.44 | **​** | **22%** |
| Adjustments: | ​ | ​ | **​** | ​ | ​ | ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ ​ |
| Special (gains) and charges, after tax | **​** |  | **0.12** | **​** | ​ | ​ | 0.29 | ​ | ​ ​ | **​** | **​** | **0.20** | **​** | ​ | ​ | 0.35 | ​ | ​ ​ |
| Discrete tax net expense (benefit) | ​ |  | **0.02** | **​** | ​ | ​ | (0.08) | ​ | ​ ​ | ​ | **​** | **0.08** | **​** | ​ | ​ | (0.15) | ​ | ​ ​ |
| Non-GAAP adjusted diluted EPS from continuing operations | ​ | **​** | **$1.22** | **​** | ​ | ​ | $ 0.65 | ​ | **88%** | ​ | **​** | **$2.03** | **​** | ​ | ​ | $ 1.64 | ​ | **24%** |

Per share amounts in the above tables do not necessary sum due to rounding.

Currency translation had a favorable impact of approximately $0.06 and $0.08 per share on diluted EPS for the second quarter and first six months of 2021, respectively, when compared to the comparable periods of 2020.

### DISCONTINUED OPERATIONS

The ChampionX business met the criteria to be reported as discontinued operations and the historical results of ChampionX, including the results of operations, are reported as discontinued operations for all periods presented. The net loss from discontinued operations, net of tax was $2,163.9 million and $2,172.5 million in the second quarter and first six months of 2020, respectively.

During the second quarter of 2020, in connection with the ChampionX Separation, Ecolab received cash of $527 million and $1,051 million of non-cash consideration of approximately 5 million shares of Ecolab common stock for the ChampionX net assets, including cumulative translation adjustment, of $3,717 million, resulting in a loss.

Special (gains) and charges of $2,186.1 million and $2,222.7 million in the second quarter and first six months of 2020, respectively primarily relate to the loss on separation, transaction fees, and other professional fees incurred to support the Transaction.

### SEGMENT PERFORMANCE

The non-U.S. dollar functional international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates used by management for 2021. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2 of our Annual Report on Form 10-K for the year ended December 31, 2020. Additional information about our reportable segments is included in Note 16.

Fixed currency net sales and operating income for the second quarter and first six months of 2021 and 2020 for our reportable segments are shown in the following tables.

| ​ Net Sales ​ (millions) | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2021 2020 ​ ​ Change | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30 2021 2020 ​ ​ Change |
| --- | --- | --- | --- | --- |
| Global Industrial | **​** | **​** **$1,555.4** **​** ​ $1,498.5 ​ **4%** | **​** | **​** **$2,989.3** **​** ​ $2,963.5 ​ **1%** |
| Global Institutional & Specialty |  | **​** **978.9** **​** ​ 733.0 ​ ​ **34** ​ |  | **​** **1,837.4** **​** ​ 1,820.2 ​ ​ **1** ​ |
| Global Healthcare & Life Sciences | **​** | **​** **303.5** **​** ​ ​ 321.4 ​ ​ **(6)** ​ | **​** | **​** **597.2** **​** ​ ​ 578.2 ​ ​ **3** ​ |
| Other | **​** | **​** **306.6** **​** ​ ​ 249.1 ​ ​ **23** ​ | **​** | **​** **577.9** **​** ​ ​ 528.7 ​ ​ **9** ​ |
| Corporate |  | **​** **35.0** **​** ​ 12.3 ​ ​ **185** ​ |  | **​** **68.2** **​** ​ 12.3 ​ ​ **454** ​ |
| Subtotal at fixed currency |  | **​** **3,179.4** **​** ​ 2,814.3 ​ ​ **13** ​ |  | **​** **6,070.0** **​** ​ 5,902.9 ​ ​ **3** ​ |
| Effect of foreign currency translation |  | **​** **(16.7)** **​** ​ (128.6) ​ ​ **​** ​ |  | **​** **(22.3)** **​** ​ (196.6) ​ ​ **​** ​ |
| Consolidated reported GAAP net sales |  | **​** **$3,162.7** **​** ​ ​ $2,685.7 ​ ​ **18%** |  | **​** **$6,047.7** **​** ​ ​ $5,706.3 ​ ​ **6%** |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | Second Quarter Ended | ​ | Six Months Ended |
| ​ | **​** | June 30 | ​ | June 30 |
| (millions) | ​ | **2021** 2020 ​ ​ **Change** | ​ | **2021** 2020 ​ ​ **Change** |
| Global Industrial |  | **$263.3** **​** ​ $287.8 **​** **(9)%** | ​ | **$482.5** **​** ​ $497.4 **​** **(3)%** |
| Global Institutional & Specialty |  | **​** **138.6** **​** ​ (38.0) **​** **\*** ​ | ​ | **​** **201.7** **​** ​ 145.7 **​** **38** ​ |
| Global Healthcare & Life Sciences | **​** | **​** **48.3** **​** ​ ​ 69.0 **​** **​** **(30)** ​ | ​ | **​** **93.9** **​** ​ ​ 93.0 **​** **​** **1** ​ |
| Other |  | **​** **51.3** **​** ​ 20.8 **​** **147** ​ | ​ | **​** **84.2** **​** ​ 42.6 **​** **98** ​ |
| Corporate |  | **​** **(51.4)** **​** ​ (128.1) ​ ​ **(60)** ​ | ​ | **​** **(114.4)** **​** ​ (183.2) ​ ​ **(38)** ​ |
| Subtotal at fixed currency |  | **​** **450.1** **​** ​ 211.5 **​** **113** ​ | ​ | **​** **747.9** **​** ​ 595.5 **​** **26** ​ |
| Effect of foreign currency translation |  | **​** **(2.3)** **​** ​ (19.5) ​ ​ **​** ​ | ​ | **​** **(2.8)** **​** ​ (27.3) ​ ​ **​** ​ |
| Consolidated reported GAAP operating income |  | **$447.8** **​** ​ ​ $192.0 **​** **133%** | ​ | **$745.1** **​** ​ ​ $568.2 **​** **31%** |

\* Not meaningful.

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

| ​ ​ ​ Net Sales (millions) | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2021 ​ 2020 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| --- | --- | ---: |
| Global Industrial | **​** | **$1,555.4** **​** **($26.2)** **​** **$1,529.2** ​ $1,498.5 ​ ($19.5) ​ $1,479.0 |
| Global Institutional & Specialty |  | **978.9** **​** **(3.2)** **​** **975.7** ​ 733.0 ​ - ​ 733.0 |
| Global Healthcare & Life Sciences | **​** | **303.5** **​** **(6.6)** **​** **296.9** ​ 321.4 ​ (0.2) ​ 321.2 |
| Other |  | **306.6** **​** **-** **​** **306.6** ​ 249.1 ​ - ​ 249.1 |
| Corporate |  | **35.0** **​** **(35.0)** **​** **-** ​ 12.3 ​ (12.3) ​ - |
| Subtotal at fixed currency |  | **3,179.4** **​** **(71.0)** **​** **3,108.4** ​ 2,814.3 ​ (32.0) ​ 2,782.3 |
| Effect of foreign currency translation |  | **(16.7)** **​** ​ **​** ​ ​ (128.6) ​ ​ ​ ​ |
| Total reported net sales |  | **$3,162.7** **​** ​ **​** ​ ​ $2,685.7 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2021** ​ 2020 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$263.3** **​** **($1.2)** **​** **$262.1** ​ $287.8 ​ ($2.3) ​ $285.5 |
| Global Institutional & Specialty |  | **138.6** **​** **0.6** **​** **139.2** ​ (38.0) ​ - ​ (38.0) |
| Global Healthcare & Life Sciences | **​** | **48.3** **​** **0.2** **​** **48.5** ​ 69.0 ​ (0.1) ​ 68.9 |
| Other |  | **51.3** **​** **-** **​** **51.3** ​ 20.8 ​ - ​ 20.8 |
| Corporate |  | **(30.1)** **​** **-** **​** **(30.1)** ​ (31.7) ​ - ​ (31.7) |
| Non-GAAP adjusted fixed currency operating income |  | **471.4** **​** **(0.4)** **​** **471.0** ​ 307.9 ​ (2.4) ​ 305.5 |
| Special (gains) and charges |  | **21.3** **​** **​** **​** **​** ​ 96.4 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **450.1** **​** **​** **​** **​** ​ 211.5 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(2.3)** **​** **​** **​** **​** ​ (19.5) ​ ​ ​ ​ |
| Total reported operating income |  | **$447.8** **​** **​** **​** **​** ​ $192.0 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| ​ | **​** | Six Months Ended |
| **​** | **​** | June 30 |
| **Net Sales** | **​** | **2021** ​ 2020 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$2,989.3** **​** **(59.3)** **​** **$2,930.0** ​ $2,963.5 ​ (36.7) ​ $2,926.8 |
| Global Institutional & Specialty |  | **1,837.4** **​** **(6.0)** **​** **1,831.4** ​ 1,820.2 ​ - ​ 1,820.2 |
| Global Healthcare & Life Sciences | **​** | **597.2** **​** **(9.1)** **​** **588.1** ​ 578.2 ​ (0.6) ​ 577.6 |
| Other |  | **577.9** **​** **-** **​** **577.9** ​ 528.7 ​ - ​ 528.7 |
| Corporate | **​** | **68.2** **​** **(68.2)** **​** **-** ​ 12.3 ​ (12.3) ​ - |
| Subtotal at fixed currency |  | **6,070.0** **​** **(142.6)** **​** **5,927.4** ​ 5,902.9 ​ (49.6) ​ 5,853.3 |
| Effect of foreign currency translation |  | **(22.3)** **​** ​ **​** ​ ​ (196.6) ​ ​ ​ ​ |
| Total reported net sales |  | **$6,047.7** **​** ​ **​** ​ ​ $5,706.3 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2021** ​ 2020 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$482.5** **​** **(2.4)** **​** **$480.1** ​ $497.4 ​ (2.4) ​ $495.0 |
| Global Institutional & Specialty |  | **201.7** **​** **1.6** **​** **203.3** ​ 145.7 ​ - ​ 145.7 |
| Global Healthcare & Life Sciences |  | **93.9** **​** **0.2** **​** **94.1** ​ 93.0 ​ (0.1) ​ 92.9 |
| Other | **​** | **84.2** **​** **-** **​** **84.2** ​ 42.6 ​ - ​ 42.6 |
| Corporate |  | **(60.7)** **​** **-** **​** **(60.7)** ​ (61.8) ​ - ​ (61.8) |
| Non-GAAP adjusted fixed currency operating income |  | **801.6** **​** **(0.6)** **​** **801.0** ​ 716.9 ​ (2.5) ​ 714.4 |
| Special (gains) and charges |  | **53.7** **​** **​** **​** **​** ​ 121.4 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **747.9** **​** **​** **​** **​** ​ 595.5 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(2.8)** **​** **​** **​** **​** ​ (27.3) ​ ​ ​ ​ |
| Total reported operating income |  | **$745.1** **​** **​** **​** **​** ​ $568.2 ​ ​ ​ ​ |

Unless otherwise noted, the following segment performance commentary compares the second quarter and first six months of 2021 against the second quarter and first six months of 2020.

### Global Industrial

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$1,555.4** ​ | ​ | ​ | $1,498.5 ​ | **​** | **​** | **$2,989.3** ​ | ​ | ​ | $2,963.5 ​ |
| Sales at public currency (millions) | **​** | **​** | **1,544.5** ​ | ​ | ​ | 1,424.3 ​ | **​** | **​** | **2,975.5** ​ | ​ | ​ | 2,857.4 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **(1)%** | **​** |  | ​ ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **3%** | **​** | ​ | ​ ​ | **​** | **​** | **0%** | **​** | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ |
| Fixed currency sales change | **​** |  | **4%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ |
| Foreign currency translation | **​** | **​** | **4%** | **​** | ​ | ​ ​ | **​** | **​** | **3%** | **​** | ​ | ​ ​ |
| Public currency sales change | **​** |  | **8%** | **​** |  | ​ ​ | **​** |  | **4%** | **​** |  | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$263.3** ​ | ​ | ​ | $287.8 ​ | **​** | **​** | **$482.5** ​ | ​ | ​ | $497.4 ​ |
| Operating income at public currency (millions) | **​** | **​** | **260.8** ​ | ​ | ​ | 272.5 ​ | **​** | **​** | **479.6** ​ | ​ | ​ | 477.3 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **(9)%** | **​** | ​ | ​ ​ | **​** | **​** | **(3)%** | **​** | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **16.9%** | **​** |  | 19.2% | **​** |  | **16.1%** | **​** |  | 16.8% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(8)%** | **​** |  | ​ ​ | **​** |  | **(3)%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **17.1%** | **​** |  | 19.3% | **​** |  | **16.4%** | **​** |  | 16.9% |
| Public currency operating income change | ​ | ​ | **(4)%** | ​ | ​ | ​ ​ | ​ | ​ | **0%** | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Industrial increased in the second quarter and first six months of 2021, as strong growth in Water and Paper, led by recovering market conditions and new business wins, as well as improving trends in Food & Beverage, more than offset lower Downstream sales that reflected low-margin refinery business exits.

At an operating segment level, ***Water*** fixed currency sales increased 7% and 4% in the second quarter and first six months of 2021, respectively, as strong new business wins leveraged recovering markets. Light industry water treatment sales showed very strong growth, led by good gains in food & beverage, light manufacturing and data centers. Heavy industry sales saw good growth driven by strong performance in primary metals. Mining declined modestly as good results from our strategic shift toward precious metals and fertilizers were more than offset by soft legacy coal and alumina markets. ***Food & Beverage*** fixed currency sales increased 2% (1% acquisition adjusted) and 2% (0% acquisition adjusted) in the second quarter and first six months of 2021, respectively, reflecting new business wins and recovering markets. Globally we realized strong recovery in beverage and brewing, stable dairy plant and protein sales, and declines in food and animal health as good underlying sales compared against COVID-19 related buying surges last year. ***Downstream*** fixed currency sales decreased 6% and 12% in the second quarter and first six months of 2021, respectively, as petrochemical sales growth, rising refinery operating rates and increased business wins were more than offset by low-margin refinery business exits. ***Paper*** fixed currency sales increased 10% and 6% in the second quarter and first six months of 2021, respectively, driven by improved end markets and strong new business wins. Board & packaging showed very strong growth and graphics recovered from last year’s sharp decline as market trends stabilized; these more than offset lower tissue sales which compared to very strong COVID-19 surge demand last year.

### Operating Income

Fixed currency operating income and fixed currency operating income margins decreased for Global Industrial in the second quarter and first six months of 2021.

Acquisition adjusted fixed currency operating income margins decreased 2.2 percentage points during the second quarter of 2021, as accelerating pricing generally offset increased delivered product cost in the quarter while the 0.7 percentage point positive impact from volume growth was more than offset by the 2.2 percentage point negative impact of higher variable compensation and Texas freeze impact. Acquisition adjusted fixed currency operating income margins decreased 0.5 percentage points during the first six months of 2021, as the 2.1 percentage point positive impacts from cost savings and favorable pricing were more than offset by the 2.5 percentage point negative impact of higher delivered product costs including the Texas Freeze and increased variable compensation.

### Global Institutional & Specialty

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$978.9** ​ | ​ | ​ | $733.0 ​ | **​** | **​** | **$1,837.4** ​ | ​ | ​ | $1,820.2 ​ |
| Sales at public currency (millions) | **​** | **​** | **976.0** ​ | ​ | ​ | 710.1 ​ | **​** | **​** | **1,833.4** ​ | ​ | ​ | 1,780.2 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **31%** | **​** |  | ​ ​ | **​** |  | **4%** | **​** |  | ​ ​ |
| Price changes | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **33%** | **​** | ​ | ​ ​ | **​** | **​** | **1%** | **​** | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** |  | ​ ​ | **​** |  | **-%** | **​** |  | ​ ​ |
| Fixed currency sales change | **​** |  | **34%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ |
| Foreign currency translation | **​** | **​** | **3%** | **​** | ​ | ​ ​ | **​** | **​** | **2%** | **​** | ​ | ​ ​ |
| Public currency sales change | **​** |  | **37%** | **​** |  | ​ ​ | **​** |  | **3%** | **​** |  | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$138.6** ​ | ​ | ​ | ($38.0) ​ | **​** | **​** | **$201.7** ​ | ​ | ​ | $145.7 ​ |
| Operating income at public currency (millions) | **​** | **​** | **138.8** ​ | ​ | ​ | (38.0) ​ | **​** | **​** | **202.0** ​ | ​ | ​ | 144.0 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **\*** **​** | **​** | ​ | ​ ​ | **​** | **​** | **38%** | **​** | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **14.2%** | **​** |  | (5.2)% | **​** |  | **11.0%** | **​** |  | 8.0% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **\*** **​** | **​** |  | ​ ​ | **​** |  | **40%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **14.3%** | **​** |  | (5.2)% | **​** |  | **11.1%** | **​** |  | 8.0% |
| Public currency operating income change | ​ | ​ | **\*** **​** | ​ | ​ | ​ ​ | ​ | ​ | **40%** | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ |

Percentages in the above table do not necessarily sum due to rounding.

\* Not meaningful

### Net Sales

Fixed currency sales for Global Institutional & Specialty increased in the second quarter and first six months of 2021. Strong growth in the Institutional operating segment reflected recovering markets, new business wins and pricing. Specialty sales declined versus last year’s strong gain that benefited from COVID-19 related orders.

At an operating segment level, ***Institutional*** fixed currency sales increased 61% and 6% (5% acquisition adjusted) in the second quarter and first six months of 2021, respectively, as the U.S. market showed an ongoing recovery in restaurant traffic. This recovery, along with recent business wins and sales initiatives, drove the strong results. While social distancing mandates eased in the U.S. through the second quarter and drove increased consumer traffic and in-unit dining, such mandates continued in many other regions as they lagged in their vaccinations and infection rate reductions, continuing to impact consumer activity. ***Specialty*** fixed currency sales decreased 6% and 8% in the second quarter and first six months of 2021, respectively, reflecting comparison to the very strong second quarter 2020 for food retail, where strong COVID-19 driven buying significantly boosted sales. Quickservice sales increased modestly as recovering global traffic more than offset sanitizer use declines from last year’s peak levels. Food retail sales declined versus the very strong demand in 2020.

### Operating Income

Fixed currency operating income and fixed currency operating income margins increased for our Global Institutional & Specialty segment in the second quarter and first six months of 2021.

Acquisition adjusted fixed currency operating income margins increased 19.5 percentage points during the second quarter of 2021, as the 21.6 percentage point positive impacts from significant volume improvement, lower bad debt expense and favorable pricing more than offset the 2.4 percentage point negative impact of increased variable compensation. Acquisition adjusted fixed currency operating income margins increased 3.1 percentage points during the first six months of 2021 as the 4.7 percentage point positive impacts from favorable pricing, lower bad debt expense and cost savings more than offset the 1.4 percentage point negative impact of increased variable compensation.

### Global Healthcare & Life Sciences

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$303.5** ​ | ​ | ​ | $321.4 ​ | ​ | **​** | **$597.2** ​ | ​ | ​ | $578.2 ​ |
| Sales at public currency (millions) | **​** | **​** | **301.8** ​ | ​ | ​ | 299.4 ​ | ​ | **​** | **594.5** ​ | ​ | ​ | 544.1 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **(10)%** | **​** |  | ​ ​ | ​ |  | **1%** | **​** |  | ​ ​ |
| Price changes | **​** |  | **3%** | **​** |  | ​ ​ | ​ |  | **2%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(8)%** | **​** | ​ | ​ ​ | ​ | **​** | **2%** | **​** | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **2%** | **​** |  | ​ ​ | ​ |  | **1%** | **​** |  | ​ ​ |
| Fixed currency sales change | **​** |  | **(6)%** | **​** |  | ​ ​ | ​ |  | **3%** | **​** |  | ​ ​ |
| Foreign currency translation | **​** | **​** | **7%** | **​** | ​ | ​ ​ | ​ | **​** | **6%** | **​** | ​ | ​ ​ |
| Public currency sales change | **​** |  | **1%** | **​** |  | ​ ​ | ​ |  | **9%** | **​** |  | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$48.3** ​ | ​ | ​ | $69.0 ​ | ​ | **​** | **$93.9** ​ | ​ | ​ | $93.0 ​ |
| Operating income at public currency (millions) | **​** | **​** | **48.2** ​ | ​ | ​ | 63.0 ​ | ​ | **​** | **93.6** ​ | ​ | ​ | 85.5 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **(30)%** | **​** | ​ | ​ ​ | ​ | **​** | **1%** | **​** | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **15.9%** | **​** |  | 21.5% | ​ |  | **15.7%** | **​** |  | 16.1% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(30)%** | **​** |  | ​ ​ | ​ |  | **1%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **16.3%** | **​** |  | 21.5% | ​ |  | **16.0%** | **​** |  | 16.1% |
| Public currency operating income change | ​ | ​ | **(23)%** | ​ | ​ | ​ ​ | ​ | ​ | **9%** | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for the Global Healthcare & Life Sciences decreased in the second quarter of 2021 compared to a 22% increase last year when sales benefited from strong COVID-19 related demand and increased in the first six months of 2021; however, underlying Healthcare and Life Sciences sales growth remained strong, driven by new business wins and increased hygiene awareness.

At an operating segment level, ***Healthcare*** fixed currency sales decreased 3% (6% acquisition adjusted) in the second quarter of 2021 and increased 4% (2% acquisition adjusted) in the first six months of 2021, reflecting the comparison against large 2020 COVID-19 sales that drove a sales increase of 15% and 11% in the second quarter and first six months of 2020, respectively. ***Life Sciences*** fixed currency sales decreased 17% and 3% in the second quarter and first six months of 2021, respectively, reflecting comparison versus the very strong second quarter and six months of 2020, when sales increased 52% and 39% respectively, driven by 2020’s extraordinary COVID-19 demand.

### Operating Income

Fixed currency operating income and fixed currency operating income margins for our Global Healthcare & Life Sciences segment decreased in the second quarter of 2021. In the first six months of 2021, fixed currency operating income increased, whereas fixed currency operating income margins decreased.

Acquisition adjusted fixed currency operating income margins decreased 5.2 percentage points during the second quarter of 2021, primarily reflecting the comparison to the very strong sales volume last year when operating income grew 110%. Acquisition adjusted fixed currency operating income margins were flat during the first six months of 2021 as the 1.9 percentage point positive impact from favorable pricing was offset by the 1.8 percentage point negative impact of unfavorable business mix and higher delivered product costs.

### Other

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ ​ | ​ ​ | ​ 2020 | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$306.6** ​ | ​ | ​ | $249.1 ​ | **​** | **​** | **$577.9** ​ | ​ | ​ | $528.7 ​ |
| Sales at public currency (millions) | **​** | **​** | **305.5** ​ | ​ | ​ | 239.6 ​ | **​** | **​** | **576.2** ​ | ​ | ​ | 512.3 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Volume | **​** |  | **21%** | **​** |  | ​ ​ | **​** |  | **8%** | **​** |  | ​ ​ |
| Price changes | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **23%** | **​** | ​ | ​ ​ | **​** | **​** | **9%** | **​** | ​ | ​ ​ |
| Acquisitions and divestitures | **​** |  | **-%** | **​** |  | ​ ​ | **​** |  | **-%** | **​** |  | ​ ​ |
| Fixed currency sales change | **​** |  | **23%** | **​** |  | ​ ​ | **​** |  | **9%** | **​** |  | ​ ​ |
| Foreign currency translation | **​** | **​** | **4%** | **​** | ​ | ​ ​ | **​** | **​** | **3%** | **​** | ​ | ​ ​ |
| Public currency sales change | **​** |  | **28%** | **​** |  | ​ ​ | **​** |  | **12%** | **​** |  | ​ ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$51.3** ​ | ​ | ​ | $20.8 ​ | **​** | **​** | **$84.2** ​ | ​ | ​ | $42.6 ​ |
| Operating income at public currency (millions) | **​** | **​** | **51.2** ​ | ​ | ​ | 20.9 ​ | **​** | **​** | **84.0** ​ | ​ | ​ | 42.2 ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ |
| Fixed currency operating income change | **​** | **​** | **147%** | **​** | ​ | ​ ​ | **​** | **​** | **98%** | **​** | ​ | ​ ​ |
| Fixed currency operating income margin | **​** |  | **16.7%** | **​** |  | 8.4% | **​** |  | **14.6%** | **​** |  | 8.1% |
| Acquisition adjusted fixed currency operating income change | **​** |  | **147%** | **​** |  | ​ ​ | **​** |  | **98%** | **​** |  | ​ ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **16.7%** | **​** |  | 8.4% | **​** |  | **14.6%** | **​** |  | 8.1% |
| Public currency operating income change | ​ | ​ | **145%** | ​ | ​ | ​ ​ | ​ | ​ | **99%** | ​ | ​ | ​ ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Other increased in the second quarter and first six months of 2021, led by strong growth in Pest Elimination that was driven by recovering markets and new business wins.

At an operating segment level, ***Pest Elimination*** fixed currency sales increased 21% and 13% in the second quarter and first six months of 2021, respectively, compared against COVID impacted sales a year-ago, as strong growth in food and beverage plants, grocery stores and quick-service restaurants leveraged a strong recovery in hospitality and full-service restaurant markets as restrictions ease. ***Textile Care*** fixed currency sales increased 34% in the second quarter of 2021 and decreased 1% in the first six months of 2021. ***Colloidal Technologies Group*** fixed currency sales increased 25% and 8% in the second quarter and first six months of 2021, respectively.

### Operating Income

Fixed currency operating income and fixed currency operating income margins for Other increased in the second quarter and first six months of 2021.

Acquisition adjusted fixed currency operating income margins increased 8.3 percentage points during the second quarter of 2021 driven by strong volume growth. Acquisition adjusted fixed currency operating income margins increased 6.5 percentage points during the first six months of 2021 driven by increased volume, cost savings and favorable pricing.

### Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 40 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 4, intangible asset amortization specifically from the Nalco merger and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 36.

### FINANCIAL POSITION, CASH FLOWS AND LIQUIDITY

### Financial Position

Total assets were $18.5 billion as of June 30, 2021 compared to total assets of $18.1 billion as of December 31, 2020.

Total liabilities were $11.8 billion as of June 30, 2021 compared to total liabilities of $11.9 billion as of December 31, 2020. Total debt was $6.7 billion as of June 30, 2021 and $6.7 billion as of December 31, 2020. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) is shown in the following table. EBITDA is a non-GAAP measures discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

The inputs to EBITDA reflect the trailing twelve months of activity for the period presented.

| ​ ​ ​ (ratio) | ​ ​ ​ | ​ ​ 2021 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ 2020 ​ | ​ ​ ​ | ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Net debt to EBITDA |  | **​** | **2.2** | **​** |  | ​ | 2.4 | ​ |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ |
| (millions) |  | **​** | **​** | **​** | ​ | ​ | ​ | ​ |
| Total debt | **​** | **​** | **$6,726.2** | **​** | ​ | ​ | $6,686.6 | ​ |
| Cash | **​** |  | **1,402.4** | **​** | ​ | ​ | 1,260.2 | ​ |
| Net debt | **​** | **​** | **$5,323.8** | **​** | ​ | ​ | $5,426.4 | ​ |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ |
| Net income including noncontrolling interest | ​ | **​** | **$1,064.3** | **​** | ​ | ​ | $984.8 | ​ |
| Provision for income taxes | **​** |  | **267.7** | **​** | ​ | ​ | 176.6 | ​ |
| Interest expense, net | **​** |  | **280.5** | **​** | ​ | ​ | 290.2 | ​ |
| Depreciation | **​** |  | **605.2** | **​** | ​ | ​ | 594.3 | ​ |
| Amortization | **​** |  | **231.9** | **​** | ​ | ​ | 218.4 | ​ |
| EBITDA | **​** |  | **$2,449.6** | **​** | ​ | ​ | $2,264.3 | ​ |

### Cash Flows

### Operating Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ | ​ | ​ Change | ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash provided by operating activities | ​ | **​** | **$798.3** | ​ | ​ | ​ | $640.2 | ​ | ​ | **​** | **$158.1** | **​** |

We continue to generate cash flow from operations amidst the COVID-19 pandemic, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases. Cash provided by operating activities increased $158 million in the first six months of 2021 compared to the first six months of 2020, driven primarily by a $37 million increase in net income from continuing operations including noncontrolling interest excluding disposal and impairment charges, $106 million decreased annual bonus payouts, $65 million net favorable fluctuations in deferred taxes, partially offset by $53 million net unfavorable fluctuations in accounts receivable, inventories and accounts payable (“working capital”). The cash flow impact from working capital accounts was primarily driven by increased sales volume, partially offset by improved days sales outstanding and improved inventory days on hand.

### Investing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ | ​ | ​ Change | ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash used for investing activities | ​ | **​** | **($347.8)** | ​ | ​ | ​ | ($689.7) | ​ | ​ | **​** | **$341.9** | **​** |

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as capital investments in the business.

Total cash paid for acquisitions, net of cash acquired along with net cash received from dispositions, during the first six months of 2021 and 2020, was $90 million and $431 million, respectively. Our acquisitions and divestitures are discussed further in Note 3. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

We continue to make capital investments in the business, including merchandising equipment, manufacturing equipment and facilities. Total capital expenditures were $246 million and $251 million in the first six months of 2021 and 2020, respectively.

### Financing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ | ​ | ​ Change | ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Cash (used for) provided by financing activities | ​ | **​** | **($318.3)** | ​ | ​ | ​ | $720.6 | ​ | ​ | **​** | **($1,038.9)** | **​** |

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $750 million par value and received $769 million in proceeds of long-term debt and repaid $300 million of long-term debt in the first six months of 2020. The proceeds received from the debt issuances were used for repayment of outstanding debt, repayment of commercial paper and general corporate purposes. In addition, we paid down $1 million and issued $454 million of commercial paper and notes payable in the first six months of 2021 and 2020, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We reacquired a total of $71 million and $105 million of shares in the first six months of 2021 and 2020, respectively. Cash proceeds and tax benefits from stock option exercises provide a portion of the funding for repurchase activity.

We paid dividends of $287 million and $283 million in in the first six months of 2021 and 2020 respectively.

The impact on financing cash flows of commercial paper and notes payable issuances and long-term debt borrowings and repayments are shown in the following table:

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Six Months Ended June 30 2021 | ​ | ​ | ​ ​ | ​ 2020 | ​ | ​ | ​ | ​ Change | ​ | ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Net issuances of commercial paper and notes payable | **​** | **​** | **($1.0)** | ​ | ​ | ​ | $454.4 | ​ | ​ | **​** | **($455.4)** | ​ |
| Long-term debt borrowings | **​** | **​** | **-** | ​ | ​ | ​ | 768.9 | ​ | ​ | **​** | **(768.9)** | ​ |
| Long-term debt repayments | **​** | **​** | **-** | ​ | ​ | ​ | (300.0) | ​ | ​ | **​** | **300.0** | ​ |

### Liquidity and Capital Resources

We currently expect to fund the cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of June 30, 2021, we had $1,402 million of cash and cash equivalents on hand, of which $44 million was held outside of the U.S. We continue to carry increased levels of cash on hand to meet current and any future potential operational cash needs as a result of the COVID-19 pandemic. We will continue to evaluate our cash position in light of future developments.

As of June 30, 2021, we have a $2.0 billion multi-year credit facility which expires in April 2026. In April 2021, we entered into an amended and restated revolving credit facility which extended the maturity from November 2022 to April 2026. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At the end of the second quarter of 2021, we had no outstanding commercial paper under our U.S.

or Euro programs. There were no borrowings under our credit facility as of June 30, 2021 or 2020. As of June 30, 2021, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

Our long-term debt issuance and repayment activity through the first six months of 2021 and 2020 is discussed in the Cash Flows – Financing Activities section of this MD&A.

We are in compliance with our debt covenants and believe we have sufficient borrowing capacity to meet our foreseeable operating activities, as needed.

The schedule of contractual obligations included in the Financial Position and Liquidity section of our Form 10-K for the year ended December 31, 2020 disclosed total notes payable and long-term debt due within one year of $17 million. As of June 30, 2021, the total notes payable and long-term debt due within one year was $17 million. There was no commercial paper outstanding as of June 30, 2021 or December 31, 2020.

Our gross liability for uncertain tax positions was $19 million as of June 30, 2021 and $21 million as of December 31, 2020. We are not able to reasonably estimate the amount by which the liability will increase or decrease over time; however, at this time, we do not expect significant payments related to these obligations within the next year.

### GLOBAL ECONOMIC ENVIRONMENT

### Coronavirus disease 2019 (COVID-19)

In March 2020, the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets and industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic, including supply shortages and inflation. While many government restrictions in the U.S. have eased through the second quarter, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a resurgence of cases triggering additional government mandated lockdowns or similar restrictions on activity, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world.

We expect the U.S. recovery to continue, Europe to reopen as forecasted, and the rest of the world to follow soon after, and we have implemented pricing actions that will build through the second half to manage inflation and rising delivered product costs. With this outlook, we expect continued strong year-on-year performance in the second half of 2021. We remain confident in our long-term outlook and believe we are well-positioned for continued future growth.

### Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina has continued to experience negative economic trends, evidenced by multiple periods of increasing inflation rates, devaluation of the peso, and increasing borrowing rates. Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During the first six months of 2021, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of the second quarter of 2021 represented less than 1% of our consolidated assets.

### NEW ACCOUNTING PRONOUNCEMENTS

For information on new accounting pronouncements, refer to Note 18 to the Consolidated Financial Statements.

### SUBSEQUENT EVENTS

Subsequent to quarter end, we acquired a US Healthcare business for approximately $120 million. The acquisition is not material to our consolidated financial statements.

In July 2021, we entered into an interest rate swap agreement that converted the remaining $250 million of our 3.25% debt from a fixed interest rate to a floating interest rate. The interest rate swap is designated as a fair value hedge.

Also in July 2021, we entered into a cross currency swap agreement with a notional amount of €300 million maturing in 2030. The cross currency swap is designated as a net investment hedge of our Euro denominated exposures from our investments in certain of our Euro denominated functional currency subsidiaries.

### NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

- Fixed currency sales
- Acquisition adjusted fixed currency sales
- Adjusted cost of sales
- Adjusted gross margin
- Fixed currency operating income
- Fixed currency operating income margin
- Adjusted operating income
- Adjusted operating income margin
- Adjusted fixed currency operating income
- Adjusted fixed currency operating income margin
- Acquisition adjusted fixed currency operating income
- Acquisition adjusted fixed currency operating income margin
- Adjusted interest expense, net
- EBITDA
- Adjusted tax rate
- Adjusted net income attributable to Ecolab
- Adjusted diluted EPS

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for cost of sales, gross margin and operating income exclude the impact of special (gains) and charges, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including noncontrolling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-Q are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2021.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, exclude the results of our divested businesses from the twelve months prior to divestiture.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

### FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the COVID-19 pandemic outlook; business performance and prospects; expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities; tax deductibility of goodwill; capital investments and acquisitions; amortization expense; non-performance of financial counterparties; payments and contributions to pension and postretirement health care benefit plans; the impact of lawsuits, claims and environmental matters; impact of new accounting pronouncements; cash flows, borrowing capacity and funding of cash requirements; payments related to uncertain tax positions; and implementation of ERP system upgrade.

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof) or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. In particular, the effects of the COVID-19 pandemic depend on numerous factors, including the severity of the disease, the duration of the outbreak, the distribution and efficacy of vaccines, the likelihood of a resurgence of the outbreak, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic or to stimulate the economy and other unintended consequences. Further, the ultimate results of any restructuring or efficiency initiative, integration and business improvement actions, including cost synergies, depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring or efficiency initiative and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

Some of the factors which could cause results to differ materially from those expressed in any forward-looking statements are set forth under Item 1A of our most recent Form 10-K, as updated by Item 1A of this Form 10-Q, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the effects of the COVID-19 pandemic; the vitality of the markets we serve; the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk and reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; potential information technology infrastructure failures or breaches in data security; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; our ability to attract, retain and develop high caliber management talent to lead our business and successfully execute organizational change; our ability to successfully compete with respect to value, innovation and customer support; exposure to global economic, political and legal risks related to our international operations; difficulty in procuring raw materials or fluctuations in raw material costs; pressure on operations from consolidation of customers or vendors; the costs and effects of complying with laws and regulations, including those relating to the environment, and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; restraints on pricing flexibility due to contractual obligations; our ability to acquire complementary businesses and to effectively integrate such businesses; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with covenants that apply to our indebtedness; public health outbreaks, epidemics or pandemics, such as the current outbreak of COVID-19; potential losses arising from the impairment of goodwill or other assets; potential chemical spill or release; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; and other uncertainties or risks reported from time to time in our reports to the SEC. There can be no assurances that our earnings levels will meet investors’ expectations. Except as may be required under applicable law, we do not undertake, and expressly disclaim, any duty to update our Forward-Looking Statements.

## Market risk

As filed, 555 characters.

We use foreign currency forward contracts, interest rate swap agreements and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in our foreign operations. We do not hold derivative financial instruments of a speculative nature or for trading purposes. For a more detailed discussion of derivative instruments, refer to Note 9, entitled “Derivatives and Hedging Transactions”, of the consolidated financial statements located under Part I, Item 1 of this quarterly report on Form 10-Q.

## Controls and procedures

As filed, 1,221 characters.

As of June 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective.

During the period April 1, 2021 through June 30, 2021, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

## Risk factors

As filed, 6,094 characters.

In our report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 26, 2021, we identify under Item 1A important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q. See the section entitled Forward-Looking Statements located on page 51 of this Form 10-Q. We may also refer to such disclosure to identify factors that may cause results to differ from those expressed in other forward-looking statements made in oral presentations, including telephone conferences and/or webcasts open to the public.

The discussion below provides updates and additions to the risk factors and should be read together with the full list of risk factors set forth in the Form 10-K.

***The COVID-19 pandemic and measures taken in response thereto have materially and adversely impacted, and we expect may continue to materially and adversely impact, our business and results of operations, and the full impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.***

Beginning in March 2020, the COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. While many of these measures have significantly eased in the U.S. through the second quarter driving increased consumer traffic and in-unit dining, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a prolonged resurgence of cases triggering additional government mandated lockdowns or similar restrictions, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. In addition, the COVID-19 pandemic continues to have a material effect on the macroeconomic environment, and there is continued uncertainty around its duration and ultimate impact.

We expect the full impact of the COVID-19 pandemic, including the extent of its effect on our business, results of operations and financial condition, to be dictated by future developments which remain uncertain and cannot be predicted, such as the severity of the disease, the duration of the outbreak, the distribution, acceptance and efficacy of vaccines, the likelihood of a resurgence of the outbreak, including as a result of emerging variants, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic or to stimulate the economy and other unintended consequences. In addition to the reduction in the demand for our products and services, the COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, including, but not limited to, the following:

- We rely on a global workforce and take measures to protect the health and safety of our employees, customers and others with whom we do business while continuing to effectively manage our employees and maintain business operations. We have taken additional measures and incurred additional expenses to protect the health and safety of our employees to comply with applicable government requirements and safety guidance. Additionally, our business operations may be disrupted if a significant portion of our workforce is unable to work safely and effectively due to illness, quarantines, government actions or other restrictions or measures responsive to the pandemic, or if members of senior management or our Board of Directors are

unable to perform their duties for an extended period of time. A significant outbreak in one of our manufacturing facilities could adversely impact our ability to make and ship products in a timely manner. Measures taken across our business operations to address health and safety may not be sufficient to prevent the spread of COVID-19 among our employee base, customers and others. Therefore, we could face operational disruptions and incur additional expenses, including devoting additional resources to assisting employees diagnosed with COVID-19 and further changing health and safety protocols and processes, that could adversely affect our business and results of operations.

- A significant number of our employees, as well as customers and others with whom we do business, continue to work remotely in response to the COVID-19 pandemic. Our business operations may be disrupted, and we may experience increased risk of adverse effects to our business, if our business operations are negatively impacted as a result of remote work arrangements, including due to cybersecurity risks or other disruption to our technology infrastructure. Further, if our key operating facilities experience closures or worker shortages as a result of COVID-19, whether temporary or sustained, our business operations could be significantly disrupted.
- Cost management and various cost-containment actions implemented across our business in response to the COVID-19 pandemic could hinder execution of our business strategy, including the deferral of planned capital expenditures, and could adversely affect our business and results of operations.
- We believe that we appropriately reserve for expected credit losses, however we cannot be certain that loss or delay in the collection of accounts receivable will not have a material adverse effect on our results of operations and financial condition.

Filed Aug 5, 2021.
Source: SEC EDGAR, the filing index for accession 0001558370-21-010420. Last ingested by Listed: Nov 13, 2026, 16:24 ET. No prices; not investment advice.
